Related Experiment Videos

Pharmacodynamics of stannous chelates administered with 99mTc-labeled chelates

Radiology
|September 1, 1979
PubMed

Insights

Tin chelates are unstable in vivo, releasing free stannous ions. These ions accumulate in bone and concentrate in damaged heart tissue, differing from technetium-99m chelates.

Area of Science:

  • Pharmacology
  • Toxicology
  • Biochemistry

Background:

  • Tin compounds are investigated for potential medical applications.
  • Understanding the in vivo behavior of tin chelates is crucial for safety and efficacy.
  • Myocardial infarction alters tissue environments, potentially affecting drug distribution.

Purpose of the Study:

  • To investigate the pharmacodynamics of various tin chelates in vivo.
  • To determine the distribution and excretion of tin ions derived from these chelates.
  • To compare the behavior of tin chelates with their corresponding technetium-99m counterparts.

Main Methods:

  • Pharmacodynamic studies were conducted in healthy rabbits and rabbits with induced myocardial infarcts.
  • Isolated myocardial tissue was used to assess tin ion localization.
  • Subcellular distribution patterns were analyzed using tissue homogenates.

Main Results:

  • Tin chelates of pyrophosphate, HEDP, DTPA, and glucoheptonate demonstrated in vivo instability, releasing free stannous ions.
  • Free stannous ions primarily localized in bone and were excreted via urine.
  • A higher concentration of tin ions was observed in infarcted myocardium compared to normal myocardium, with mitochondrial entry noted.

Conclusions:

  • The pharmacodynamics of tin chelates are characterized by the release of free stannous ions.
  • Stannous ions exhibit specific tissue distribution, with accumulation in bone and infarcted myocardium.
  • Tin chelates possess distinct pharmacokinetic profiles compared to their 99mTc analogues.

Related Concept Videos